BIO - bio-rad.com Company Cash on Hand

bio-rad.com - graphic logo of issuer BIO

Bio-Rad Laboratories (BIO) maintains stable income through a balance between clinical diagnostics and scientific research. A "razor-and-blade" model featuring high-margin reagents ensures customer loyalty. The volume of highly liquid cash clearly confirms financial stability, where the 1.35 mark records this indicator. The company is currently optimizing capital and developing R&D to scale its diagnostic portfolio.

Company Cash Funds: Bio-Rad Laboratories, Inc. (BIO) for 07/04/2022 - 11/21/2026

Analytical breakdowns for Bio-Rad Laboratories, Inc. (BIO)

- stock quotes and analyst forecast:
Analysis of all company metrics:BIO Bio-Rad Laboratories
Brand item of Bio-Rad

Investors assess the financial autonomy of a business by analyzing liquid assets, which ensure stability during periods of external financing shortages. This indicator aggregates cash and cash equivalents, and given the minimal M&A activity of Bio-Rad Laboratories (BIO) and its focus on organic growth, the company's cash volume serves as a gauge for capital management efficiency without the excessive accumulation of non-working assets.